Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biogen’s Tecfidera Resilience Reflects ‘Inefficiencies In US System’

Payment Quirk Also Means Doctors Currently ‘May Prefer Vumerity’

Executive Summary

Analysts in Q3 pounced on a quirk in the complex US healthcare system that has provided small relief to Biogen’s much-depleted Tecfidera franchise in the US in the face of many generic rivals.

You may also be interested in...



Federal Circuit Cements Viatris Victory Over Biogen On Key US Tecfidera Patent

As anticipated by the street, Viatris has prevailed over Biogen on the originator’s appeal of a district court ruling that invalidated a key US patent shielding its Tecfidera treatment for multiple sclerosis. However, the Federal Circuit was not aligned on its decision.

Viatris Plots January Investor Day To Flesh Out Longer-Term Roadmap

Viatris will host another investor day, to take place early in the new year, to discuss its 2022-23 and 2024+ plans. Management provided details during the company’s Q3 earnings call, as Viatris announced it was once again raising full-year financial targets.

What’s Next? Five Things To Look Out For In November

In November, ANI Pharmaceuticals is hoping to complete a major acquisition, Viatris may shed further light on the state of the US generics industry and Generics Bulletin will host its eighth annual Global Generics & Biosimilars Awards, this year once again in person.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151354

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel